NCT01689766 is a Phase 2 clinical trial of Technetium Tc 99m EC20 in Metastatic Renal Cell Carcinoma, sponsored by Endocyte.

Who is sponsoring NCT01689766?

NCT01689766 is sponsored by Endocyte.

What drugs are being tested in NCT01689766?

Interventions in NCT01689766: Technetium Tc 99m EC20.

What condition does NCT01689766 study?

NCT01689766 studies Metastatic Renal Cell Carcinoma.

Is NCT01689766 still recruiting?

NCT01689766 is currently completed. Last updated 24 July 2023.

Last reviewed 2023-07-24 · How we verify

NCT01689766

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Screening Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma

Completed Phase 2 Last updated 24 July 2023

What this trial tests

Phase 2 trial testing Technetium Tc 99m EC20 in Metastatic Renal Cell Carcinoma in 150 participants. Completed.

Timeline

1 November 2003

Primary endpoint
1 November 2007

Quick facts

Lead sponsor	Endocyte
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	150
Start date	1 November 2003
Primary completion	1 November 2007
Sites	2 locations across United States

Drugs / interventions tested

Technetium Tc 99m EC20 — full drug profile →

Conditions studied

Metastatic Renal Cell Carcinoma — all drugs for Metastatic Renal Cell Carcinoma →

Sponsor

Endocyte — full company profile →

Who can join

18 and older, any sex, with Metastatic Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 2, multi-center, open-label, single-treatment group, baseline-controlled study to identify subjects with Folate Receptor-Positive Metastatic Renal Cell Carcinoma

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Folate Receptor Alpha-A Novel Approach to Cancer Therapy.
Gonzalez T, Muminovic M, Nano O, Vulfovich M. · · 2024 · cited 52× · PMID 38256120 · DOI 10.3390/ijms25021046
Development and evaluation of a new modular nanotransporter for drug delivery into nuclei of pathological cells expressing folate receptors.
Slastnikova TA, Rosenkranz AA, Khramtsov YV, Karyagina TS, et al · · 2017 · cited 16× · PMID 28490863 · DOI 10.2147/dddt.s127270

Verify or expand the search:

Other recruiting trials for Metastatic Renal Cell Carcinoma

Currently open trials in the same condition.

NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic · NA · recruiting
NCT06500455 — Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to · Phase 3 · recruiting

Other Endocyte trials

Trials by the same sponsor.

NCT04597411 — Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer · Phase 1 · recruiting
NCT03511664 — Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer · Phase 3 · completed
NCT03042312 — Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy · Phase 2 · terminated
NCT03011320 — An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery · Phase 1 · completed
NCT01170650 — Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01689766 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Endocyte
Last refreshed: 24 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01689766.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing